Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multicenter, open-label, randomized ,controlled phase III study to compare preoperative and postoperative with FOFLOX4 chemotherapy and postoperative with FOFLOX4 chemotherapy in patients with resectable liver metastasis from colorectal cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong General Hospital; Guangdong Provincial People's Hospital

Criteria

Inclusion Criteria:

1. Resectable liver metastasis from colorectal cancer(the distance from the tumor lower edge to anal more than 12cm),no visible extrahepatic metastatic tumors. Curable by resection, as determined by a surgeon and imaging physicians. The minimum of the liver metastases needs ≥2cm. Patients can be recruited if meet the conditions about:

• Primary tumor had been removed of the metachronous liver metastasis patients and no residue from the eyes or microscope.

• Primary tumor has been removed more than 1 month of the simultaneous liver metastasis patients.

2. Age of≥18 and ≤80

3. ECOG≤2

4. Signed written informed consent

Exclusion Criteria:

1. Peripheral neuropathy(CTC>1)

2. Had a neurological or mental disorders

3. Active infection

4. Allergy to Platinum-based and other drugs

5. Other acute diseases including infection, heart-disease(CHF, stable or unstable angina)

6. Pregnant or nursing patients